Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 240

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 240
---
2,814 3,603 Other non-current assets518 518 Operating lease liabilities, net(512)(502)Accounts payable and accrued liabilities(9,773)(132)Other liabilities202 — Net cash used in operating activities(59,550)(59,663)Investing activities:Purchases of property and equipment(1,654)(3,972)Purchases of short-term investments(36,482)(64,439)Maturities of short-term investments63,338 151,617 Net cash provided by investing activities25,202 83,206 Financing activities:Issuance of common stock upon exercise of stock options— 78 Proceeds from issuance under employee stock purchase plan146 408 Deferred offering costs paid for financing(16)(160)Net cash provided by financing activities130 326 Net (decrease) increase in cash, cash equivalents and restricted cash(34,218)23,869 Cash, cash equivalents and restricted cash at beginning of year62,952 39,083 Cash, cash equivalents and restricted cash at end of year$28,734 $62,952 

The accompanying notes are an integral part of these consolidated financial statements.

120

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows (continued)

(in thousands)

Year Ended December 31,20242023Supplemental disclosure of cash flow information:Interest paid during the period$211 $230 Supplemental disclosure of non-cash activities:Deferred transaction costs included in accounts payable and accrued liabilities$35 $46 Amounts accrued for purchases of property and equipment$1,153 $571 

The accompanying notes are an integral part of these consolidated financial statements.

121

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of Organization and Operations

Whitehawk Therapeutics, Inc. is an oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. The Company has a deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, and taking product candidates from the clinic to approval, launch, and commercialization.Current ADC BusinessOn December 19, 2024, the Company entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics